



miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1

Demetris Koutalianos, Andrie Koutsoulidou, Chrystalla Mytidou, Andrea C Kakouri, Anastasis Oulas, Marios Tomazou, Tassos C Kyriakides, Marianna Prokopi, Konstantinos Kapnisis, Nikoletta Nikolenko, et al.

► To cite this version:

Demetris Koutalianos, Andrie Koutsoulidou, Chrystalla Mytidou, Andrea C Kakouri, Anastasis Oulas, et al.. miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1. *Molecular Therapy - Methods and Clinical Development*, 2021, 23, pp.169 - 183. 10.1016/j.omtm.2021.09.007 . hal-03753545

HAL Id: hal-03753545

<https://hal.sorbonne-universite.fr/hal-03753545>

Submitted on 18 Aug 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1

Demetris Koutalios,^{1,17} Andrie Koutsoulidou,^{1,2,17} Chrystalla Mytidou,^{1,2} Andrea C. Kakouri,^{2,3,4} Anastasis Oulas,^{2,3} Marios Tomazou,^{2,3,4} Tassos C. Kyriakides,⁵ Marianna Prokopi,^{6,7} Konstantinos Kapnisis,⁶ Nikoleta Nikolenko,⁸ Chris Turner,⁸ Anna Lusakowska,⁹ Katarzyna Janiszewska,¹⁰ George K. Papadimas,¹¹ Constantinos Papadopoulos,¹¹ Evangelia Kararizou,¹¹ George M. Spyrou,^{2,3} Geneviève Gourdon,¹² Eleni Zamba Papanicolaou,^{2,13} Grainne Gorman,¹⁴ Andreas Anayiotos,⁶ Hanns Lochmüller,^{15,16} and Leonidas A. Phylactou^{1,2}

¹Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus, PO Box 23462, 1683 Nicosia, Cyprus; ²The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus, PO Box 23462, 1683 Nicosia, Cyprus; ³Department of Bioinformatics, The Cyprus Institute of Neurology and Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus, PO Box 23462, 1683 Nicosia, Cyprus; ⁴Department of Neurogenetics, The Cyprus Institute of Neurology and Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus, PO Box 23462, 1683 Nicosia, Cyprus; ⁵Yale Center for Analytical Sciences, Yale School of Public Health, 300 George Street, Suite 555, New Haven, CT 06520, USA; ⁶Department of Mechanical Engineering and Materials Science and Engineering, Cyprus University of Technology, 45 Kitiou Kyprianou Str., 3041 Limassol, Cyprus; ⁷Theramir Ltd, 13 Georgiou Karaiskaki Str., 3032 Limassol, Cyprus; ⁸National Hospital for Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK; ⁹Department of Neurology, Medical University of Warsaw, Warsaw, Poland; ¹⁰Department of Neurology, Central Hospital of Medical University of Warsaw, Warsaw, Poland; ¹¹Department of Neurology, Eginitio Hospital, Medical School of Athens, 74 Vasilissis Sofias, 11528 Athens, Greece; ¹²Inserm, Sorbonne University, Institute of Myology, Center of Research in Myology, Paris, France; ¹³Neurology Clinic D, The Cyprus Institute of Neurology and Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus, PO Box 23462, 1683 Nicosia, Cyprus; ¹⁴Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, University of Newcastle, Newcastle, UK; ¹⁵Department of Neuropediatrics and Muscle Disorders, Medical Centre—University of Freiburg, Faculty of Medicine, Freiburg, Germany; ¹⁶Children's Hospital of Eastern Ontario Research Institute, Division of Neurology, Department of Medicine, The Ottawa Hospital, and Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada

Myotonic dystrophy type 1 (DM1) is the most common adult-onset muscular dystrophy, primarily characterized by muscle wasting and weakness. Many biomarkers already exist in the rapidly developing biomarker research field that aim to improve patients' care. Limited work, however, has been performed on rare diseases, including DM1. We have previously shown that specific microRNAs (miRNAs) can be used as potential biomarkers for DM1 progression. In this report, we aimed to identify novel serum-based biomarkers for DM1 through high-throughput next-generation sequencing. A number of miRNAs were identified that are able to distinguish DM1 patients from healthy individuals. Two miRNAs were selected, and their association with the disease was validated in a larger panel of patients. Further investigation of miR-223-3p, miR-24-3p, and the four previously identified miRNAs, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p, showed elevated levels in a DM1 mouse model for all six miRNAs circulating in the serum compared to healthy controls. Importantly, the levels of miR-223-3p, but not the other five miRNAs, were found to be significantly downregulated in five skeletal muscles and heart tissues of DM1 mice compared to controls. This result provides significant evidence for its involvement in disease manifestation.

INTRODUCTION

Muscular dystrophies are a group of heterogeneous genetic disorders characterized by progressive loss of skeletal muscle mass. The most common form of muscular dystrophy in adults is myotonic dystrophy type 1 (DM1), affecting ~1 in 8,000 individuals globally. DM1 is an inherited autosomal dominant neuromuscular disorder with increasing disease severity through the generations.¹ The disease initially affects the skeletal muscles, causing progressive skeletal muscle weakness, wasting, and myotonia. Furthermore, DM1 is a multi-systemic disorder with many clinical symptoms including heart and central nervous system (CNS) abnormalities.² DM1 is caused by a trinucleotide CTG repeat expansion located in the 3' UTR of the *dystrophin myotonic protein kinase* (*DMPK*) gene.^{3,4} Healthy individuals have 5–35 CTG triplets, whereas the number of repeats in DM1 patients varies from 50 to over 1,000 triplets. Individuals with

Received 28 January 2021; accepted 7 September 2021;
<https://doi.org/10.1016/j.omtm.2021.09.007>

¹⁷These authors contributed equally

Correspondence: Leonidas A. Phylactou, Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, 6 Iroon Avenue, 2371 Ayios Dometios, Nicosia, Cyprus, PO Box 23462, 1683 Nicosia, Cyprus.

E-mail: laphylac@cing.ac.cy



36–49 repeats are asymptomatic with a high risk to have offspring with DM1 syndrome.⁵

Genetic tests combined with electromyography, skeletal muscle histopathology, and magnetic resonance are currently the gold standard for the diagnosis of DM1.⁶ Creatine kinase activity is the only biochemical marker measured in DM1 patients, but it is not a disease-specific marker and it is not increased in all the patients.^{7–9} Moreover, alternative splicing alterations in skeletal muscle tissue have been proposed as disease biomarkers; however, this requires an invasive procedure that causes discomfort and pain to the patients.¹⁰ To date, limited studies have been performed regarding the development of non-invasive biomarkers for DM1, showing promising results on the potential use of microRNAs (miRNAs) as candidate biomarkers.^{11–15} miRNAs are small non-coding RNA molecules that regulate numerous biological processes, through mRNA degradation or repression of translation, leading to the regulation of protein production. miRNAs were reported to circulate stably in blood and suggested as candidate biomarkers for the diagnosis, prognosis, or monitoring of various diseases.^{16–19} The stability of miRNAs in blood has been ascribed either to the formation of complexes with proteins or to their encapsulation within membrane-bound vesicles, such as exosomes.^{20–22}

In DM1, several miRNAs, including miR-1, miR-27b, miR-133a, miR-133b, miR-140-3p, miR-206, miR-454, and miR-574, were reported to be deregulated in DM1 patients compared to healthy individuals. These results suggest that they can be used as diagnostic biomarkers for DM1.^{13,14,23,24} Moreover, four miRNAs, miR-1, miR-133a, miR-133b, and miR-206, that are highly expressed in muscle tissues and are also known as myomiRs, were previously reported by our group to be increased in the serum of DM1 patients with progressive muscle wasting compared to patients with non-progressive muscle wasting, suggesting their use as monitoring biomarkers for the progression of the disease.¹¹ Importantly, we reported that the four myomiRs are encapsulated within small extracellular vesicles (EVs), which were found to be enriched in exosomes, in the blood of DM1 patients and their levels are correlated to the progression of the disease.¹²

The aim of this study was to identify novel serum-based biomarkers for DM1 by analyzing for the first time the entire small RNA population in the serum of DM1 patients and healthy individuals. Using high-throughput small RNA next-generation sequencing (NGS) analysis, we identified a unique signature of miRNAs that are altered in the serum of DM1 patients in comparison to healthy participants. After bioinformatics analysis, we identified two miRNAs, miR-24-3p and miR-223-3p, with high potential to be used as biomarkers in DM1. We further validated the levels of these two miRNAs in a larger cohort of patients and showed that the levels of miR-223-3p and miR-24-3p are elevated in the serum of DM1 patients compared to healthy individuals. We next examined the levels of miR-223-3p, miR-24-3p, and the previously identified four myomiRs, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p, in

the DM1 animal model DMSXL mice. We showed that the circulating levels of all six miRNAs are elevated in the serum of the DMSXL mice compared to healthy mice. Notably, increased circulating levels of the same miRNAs were detected in the bloodstream of DMSXL mice relative to controls and encapsulated in small EVs, in agreement with the findings in DM1 patients and normal individuals.¹² By examining the levels of these six miRNAs in the skeletal muscles and heart of DMSXL mice, we showed that only the levels of miR-223-3p are downregulated in these tissues in DMSXL mice, thus providing significant evidence for its involvement in the pathogenesis of DM1.

RESULTS

miR-223-3p and miR-24-3p levels are elevated in the serum of DM1 patients compared to healthy individuals

Small RNA NGS was initially performed to profile the entire spectrum of small RNA molecules, including miRNAs, present in serum samples of nine DM1 patients and eight gender- and age-matched healthy participants (Table S1). All the samples underwent NGS analysis to identify their small RNA content, revealing an average of total 7,034,228 reads per run. Bioinformatics analysis of the small RNA NGS data revealed a number of circulating miRNAs whose levels are either higher or lower in DM1 patients compared to healthy individuals (Figure 1). Since the RNA NGS run was performed on a low number of samples, miRNAs were selected for further investigation based on the uncorrected p values with significant difference ($p < 0.05$) between DM1 patients and healthy individuals. The miRNAs were further analyzed in order to select the subset of the best biomarker candidates for validation in a larger number of samples. The first criterion used to narrow down the list of the identified miRNAs was their abundance in serum, thus ensuring accurate detection by real-time PCR. Their abundance in serum was evaluated based on their counts per million reads revealed by the NGS analysis. The second criterion was the expression of the identified miRNAs in skeletal muscle tissue. Since DM1 is a disorder primarily affecting skeletal muscles, we excluded the identified miRNAs that were poorly expressed in muscle tissues.

Based on these criteria, two miRNAs, miR-223-3p and miR-24-3p, were chosen for experimental validation in a larger number of patients by real-time PCR. All patients were previously diagnosed with DM1, characterized with variable disease severity, progression, and age of onset, and assigned a Muscular Impairment Rating Scale (MIRS) grade (Table S1). Both miR-223-3p and miR-24-3p showed a statistically significant difference between the DM1 patients and healthy individuals in small RNA NGS analysis ($p < 0.05$) and are highly expressed in skeletal muscle tissue, known to promote muscle cell differentiation (Figure 1).^{25–29} Notably, miR-223-3p was also reported to be dysregulated in skeletal muscle tissues affected by another muscular dystrophy, Duchenne muscular dystrophy (DMD), in both the DMD animal model mdx mice and DMD patients.³⁰




Figure 1. Heatmap of the most differentially expressed miRNAs and hierarchical clustering

Nine DM1 and eight gender- and age-matched healthy participants were analyzed by NGS. The controls group (healthy individuals) is shown in gray color, and the DM1 patients group is shown in black color. The color key panel shows the Z score values calculated for each miRNA by subtracting the row mean and then dividing by the standard deviation. Z scores describe the expression of each miRNA in relation to the mean. Overexpressed miRNAs are shown in red and underexpressed miRNAs in blue. White color indicates expression change close to 0. miRNAs in red font were selected for further analysis.

gender, age of onset, severity, progression, and MIRS grade of the patients (Figures S3 and S4).

The circulating levels of miR-24-3p, miR-223-3p, and the four myomiRs are elevated in the serum of DMSXL mice

miRNAs were reported to circulate in the blood in a cell-free manner either encapsulated within membranous particles, such as exosomes, or in complexes with proteins.^{22,34–36} We have previously reported that the four myomiRs, miR-1, miR-133a, miR-133b, and miR-206, are promising monitoring biomarkers for DM1 since they were detected to be increased in the blood circulation of DM1 patients.¹¹ Although there are some promising reports regarding the presence of circulating biomarkers in DM1 patients, there is no information regarding any disease biomarkers in DM1 mouse models. The establishment of blood biomarkers in disease mouse models would allow proper monitoring of their symptoms during the development of therapeutic strategies, thus enabling the efficient assessment of candidate drugs and therapies before clinical trials. Several DM1 mouse models have been developed, but few recapitulate the multisystemic character of the disease, with DMSXL being one of them.^{37,38} DMSXL mice are transgenic mice carrying the human DM1 locus with over 1,000 CTG repeats. Mice that carry both transgenes (homozygous; DMSXL) exhibit the majority of DM1 symptoms, whereas mice that have one (heterozygous) or no (wild type; WT) copy of the transgene do not show any of the DM1 symptomatology.^{39,40} In this study, gender- and age-matched DMSXL and WT mice were employed to further examine miR-223-3p, miR-24-3p, and the four myomiRs as possible biomarkers in the DMSXL mouse model. Total RNA, enriched in miRNAs, was extracted from the serum of 6-week-old DMSXL and WT mice and investigated for the presence of the six miRNAs. At this age, DMSXL mice of both genders weigh 8–12 g, whereas WT mice of the same litter weigh 16–18 g. For the normalization of the six miRNA levels, spike-in control cel-miR-39 was employed. Statistical analysis revealed that exogenous cel-miR-39 is independent of

Serum samples were isolated from sixty DM1 patients and sixty healthy participants, followed by miRNA extraction. Real-time PCR analysis showed that the levels of miR-223-3p and miR-24-3p are significantly elevated in the serum samples of DM1 patients compared to healthy participants ($p < 0.001$) (Figures 2A and 2B; Figure S2). The levels of these two miRNAs were normalized to the levels of the ubiquitously expressed miR-16-5p, which was used as an internal control.^{31–33} In order to confirm that miR-16-5p is a suitable normalization control for the two miRNAs, statistical analysis was performed showing no correlation of miR-16-5p levels with age ($p \approx 0.68$), DM1 pathology, and gender (Figure S1). Receiver operating characteristic (ROC) analysis was obtained by plotting the true positive (sensitivity) versus false positive ($1 - \text{specificity}$). The area under the curve (AUC > 0.98 for miR-223-3p and > 0.86 for miR-24-3p) suggests that the serum levels of miR-223-3p and miR-24-3p can discriminate DM1 patients from healthy individuals with high specificity (Figures 2C and 2D). Additional statistical analysis revealed that both miR-223-3p and miR-24-3p levels are independent of

gender, age of onset, severity, progression, and MIRS grade of the patients (Figures S3 and S4).




Figure 2. miR-223-3p and miR-24-3p levels are elevated in the serum of DM1 patients

Serum samples from sixty DM1 patients and sixty healthy participants were analyzed with real-time PCR for the presence of miR-223-3p and miR-24-3p. (A and B) Distribution charts of miR-223-3p (A) and miR-24-3p (B) levels in DM1 patients and healthy participants show elevated levels of the two miRNAs in DM1 patients' serum compared to healthy participants. Horizontal lines inside the boxes mark the medians. Mean expression values are marked with rhombus. Two-sided $P > |Z|$ p values of Wilcoxon test are indicated in the boxes. *** $p < 0.0001$. (C and D) ROC curve analyses using serum miR-223-3p (C) and miR-24-3p (D) for discriminating healthy participants from DM1 patients. AUC values suggest that serum levels of miR-223-3p and miR-24-3p can discriminate DM1 patients from healthy individuals extremely well.

the DM1-related pathology in mice (Figure S5A). Real-time PCR analysis revealed that the six miRNAs under investigation are elevated in the serum of DMSXL mice in comparison to the unaffected controls (Figure 3).

The miR-223-3p, miR-24-3p, and four myomiR encapsulated levels within small EVs are increased in the serum of DMSXL mice

We have previously reported that the whole population of the four myomiRs is encapsulated within circulating small EVs, enriched in exosomes, in the serum of DM1 patients.¹² We therefore next investigated whether the levels of the six miRNAs, miR-24-3p, miR-223-3p, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p, that are elevated in the blood of DM1 patients and DMSXL mice are also encapsulated within small EVs circulating in the blood of mice. EVs were initially isolated from the serum of 6-week-old mice by employing a commercial polymer-based precipitation method. The purity of this method is not optimal, since it isolates vesicular and non-vesicular components of the serum, including exosomes. Scanning electron microscopy (SEM) and protein analysis of the exosomal marker proteins indicated that the isolated serum small EVs contain exosomes (Figure 4). SEM micrographs of the small EVs revealed round exosome-like structures (Figure 4A). The diameter of the isolated small EVs was determined by tunable resistive pulse sensing (TRPS) analysis to range from 70 to 140 nm, with the majority of them in the range of 90–110 nm, similar to previously described exosomes (Figure 4B).⁴¹ The isola-

tion of small EVs was further confirmed by western blot for the exosomal marker proteins. The exosomal marker molecules CD63, CD81, and TSG101 were detected in the small EV samples at higher amounts compared to whole cell lysate extracts, further supporting the presence of exosomes in the lysates (Figure 4C). After the analysis of the small EV properties, we investigated whether the six miRNAs, miR-24-3p, miR-223-3p, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p, are encapsulated within the small EVs in the serum of 6-week-old DMSXL and WT littermates. Real-time PCR analysis confirmed the presence of all six miRNAs within the small EVs isolated from the serum of both DMSXL and WT mice (Figures 4D–4I). Importantly, the encapsulated levels of the six miRNAs were found to be significantly elevated in the serum of DMSXL mice compared to control mice ($p < 0.05$) (Figures 4D–4I). The spike-in control cel-miR-39 was used for the normalization of the six miRNA levels within the small EVs. Statistical analysis confirmed that cel-miR-39 levels are stable in all EV samples (Figure S5B). We next investigated whether the differences in the six miRNA levels encapsulated within small EVs observed between the DMSXL and control samples are associated with the different number of small EVs circulating in the serum of the affected and unaffected mice. Quantification analysis with the TRPS method therefore followed, showing that the small EVs isolated from the serum of either DMSXL or WT mice do not have significant differences (Figure S6A). Subsequent normalization of the six miRNA levels over the number of small EVs confirmed that small membranous vesicles isolated from the serum of DMSXL mice are highly abundant in miRNAs relative to the WT mice (Figures S6B–S6G). Consequently, the elevated miRNA levels encapsulated in serum small EVs of the affected mice are possibly associated with the increased packaging of the specific miRNAs in the small EVs in the tissues of origin of the circulating EVs, which may be related to the DM1 multisystemic pathogenesis.




Figure 3. Cell-free miR-223-3p, miR-24-3p, and the four myomiRs are increased in the bloodstream of DMSXL mice

Total RNA, enriched in miRNAs, was isolated from serum samples of 6-week-old DMSXL and WT mice ($n = 5$) and analyzed for the abundances of miR-223-3p (A), miR-24-3p (B), miR-1-3p (C), miR-133a-3p (D), miR-133b-3p (E), and miR-206-3p (F). All miRNA levels were found to be elevated in DMSXL serum samples compared to WT mice. Graphs represent the relative expression of miRNA levels in DMSXL mice compared to controls.

miR-223-3p is downregulated in skeletal muscle and heart tissues of DMSXL mice

After the identification of the six elevated miRNA levels in small EVs circulating in the blood of DMSXL mice compared to controls, their endogenous levels in five skeletal muscles of mouse hindlimbs were next investigated, to identify any disease-related alterations of the miRNA expression in DM1-affected tissues. More specifically, tibialis anterior (TA), soleus, extensor digitorum longus (EDL), gastrocnemius, and quadriceps were collected from 6-week-old DMSXL and WT mice and analyzed for the endogenous levels of miR-223-3p, miR-24-3p, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p. The endogenous levels of the six miRNAs were normalized over the endogenous control, snoR-135. Statistical analysis showed that the levels of snoR-135 are stable between skeletal muscle tissues of DMSXL and WT mice (Figures S7A–S7E). Analysis of the real-time PCR data revealed that miR-223-3p levels expressed in all five skeletal muscle tissues are significantly decreased in DMSXL mice as opposed to littermate controls ($p < 0.05$) (Figure 5A). In contrast, the endogenous expression levels of miR-24-3p and the four myomiRs, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p, showed no difference between DMSXL mice and controls (Figures 5B–5F).


The heart is a smooth muscle tissue affected in DM1 patients.^{42,43} The two miRNAs identified in the present study, miR-223-3p and miR-24-3p, were previously reported to be expressed in heart tissue and to regulate cardiac fibrosis after myocardial infarction.^{25,44,45} miR-

24-3p was also reported to act as a pro-survival molecule that inhibits the apoptosis of cardiomyocytes.⁴⁶ Furthermore, the four myomiRs, miR-1, miR-133a, miR-133b, and miR-206, were found to be involved in the development of heart diseases.^{47,48} The endogenous expression levels of the six miRNAs in heart tissues of DMSXL and WT mice were therefore examined next. Total RNA, enriched in miRNAs, was isolated from the heart tissues of 6-week-old DMSXL mice and controls and analyzed for the endogenous levels of the six miRNAs. The endogenous levels of miR-223-3p in the heart tissue of DMSXL mice were significantly decreased compared to asymptomatic mice

($p < 0.05$) (Figure 6A). In contrast, the endogenous levels of miR-24-3p, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p showed no significant difference between heart tissues of DMSXL mice and littermate controls, similar to the results obtained from the investigation of the five skeletal muscles (Figures 6B–6F).

The six miRNAs are predicted to target a diverse set of genes and biological processes

The human miR-223-3p and miR-24-3p identified as biomarkers in DM1 patients in our study were screened computationally against a number of available miRNA databases to identify known and predicted gene targets and to provide information regarding their involvement in biological pathways. Through this analysis five gene targets were predicted to be common in both miR-24-3p and miR-223-3p (*ZXDA*, *EMC2*, *ERCC6L2*, *MARCHF10*, and *PLEKHH2*) (Figure 7A). The same analysis was also performed for the mouse miRNAs, miR-24-3p, miR-223-3p, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p, revealing a number of unique and shared predicted gene targets (Figure 7B). miR-133a-3p and miR-133b-3p were predicted to share almost the same gene targets, as they differ by a single nucleotide at the 3' end, and therefore these two miRNAs were grouped as miR-133. Most of the targets of miR-206 are common with miR-1-3p, due to the fact that these miRNAs share the same seed region and differ by only four nucleotides. Considering the four myomiRs analyzed, miR-1-3p and miR-133-3p share a common gene target, whereas miR-1-3p, miR-133-3p, and miR-206-3p



(legend on next page)




Figure 5. The endogenous levels of miR-223-3p are decreased in five skeletal muscle tissues in DMSXL mice

Five skeletal muscle tissues, TA, soleus, EDL, gastrocnemius, and quadriceps, located on the hindlimbs of 6-week-old DMSXL and control mice ($n = 5$) were harvested and analyzed for the endogenous levels of miR-223-3p (A), miR-24-3p (B), miR-1-3p (C), miR-133a-3p (D), miR-133b-3p (E), and miR-206-3p (F). miR-223-3p expression levels were decreased in all five skeletal muscle tissues of DMSXL mice compared to WT mice. The endogenous levels of miR-24-3p and the four myomiRs showed no significant changes in DMSXL mice as opposed to controls. Graphs represent the relative expression of miRNA levels in DMSXL mice relative to WT mice. * $p < 0.05$.

share two common gene targets in mice. Furthermore, one gene target is common in miR-1-3p, miR-206-3p, and miR-24-3p (*Matr3*), two gene targets are common in miR-1-3p, miR-206-3p, and miR-223-3p (*Eva1a* and *Hsp90b1*), and three targets are common in miR-133-3p and miR-223-3p (*Gla2*, *Septin6*, and *Tm45f1*) (Figure 7B).

To investigate the potential functional and biological impact when these gene targets are dysregulated, a functional analysis using the PANTHER Classification System through the Gene Ontology (GO) web server was next performed.^{49,50} The functional analysis aimed to identify the most relevant GO biological processes in which the predicted target genes of the dysregulated miRNAs are involved. The most enriched GO biological processes (levels 4 up to 16) were found to relate to muscle and neuron developmental and functional processes (Figures 7C–7F). In all miRNA groups tested (hsa-miR-24-3p and hsa-miR-223-3p; mmu-miR-24-3p and mmu-miR-223-3p; mmu-miR-1-3p, mmu-miR-133a-3p, mmu-miR-133b-3p, and

mmu-miR-206-3p), we found several such related processes, although mmu-miR-24-3p was predicted to be involved in most biological processes of interest (Figure 7D). Although the two mouse miRNAs, miR-24-3p and miR-223-3p, were predicted to regulate common biological processes such as development of the nervous system, several non-overlapping processes were also predicted (Figures 7D and 7E). An example of these biological processes is the involvement of miR-223-3p in response to stress in cardiac muscle adaptation and cardiac muscle

hypertrophy. The full set of the predicted gene targets and the corresponding functional analysis are given in the Supplemental information (Tables S2, S3, S4, and S5).

DISCUSSION

DM1 is the most common type of muscular dystrophy in adults and the second most common type of muscular dystrophy, after DMD. In recent years, emphasis has been placed on examining the potential use of circulating miRNAs as a promising tool for the diagnosis and monitoring of various diseases, including muscular dystrophies.^{15,51} Although there are several studies focusing on the development of biomarkers in muscular dystrophies, few reports exist regarding the use of such circulating miRNAs as biomarkers for DM1.^{11–14,23,24} Initially, nine miRNAs were found to be deregulated in plasma of DM1 patients compared to control subjects and suggested as diagnostic biomarkers for DM1.¹³ In a following report, we showed that the levels of four myomiRs, miR-1-3p, miR-133a-3p, miR-133b-3p,

Figure 4. The levels of miR-223-3p, miR-24-3p, and the four myomiRs are elevated in serum small EVs of DMSXL mice

(A) Small EVs isolated from serum samples of 6-week-old DMSXL and control mice were imaged by SEM. SEM images at 60,000 $\times$ magnification revealed rounded exosome-like structures. Scale bar, 500 nm. (B) Quantification and size analysis of serum small membranous particles using TRPS showed that small EVs isolated from murine serum were within the size range of exosomes. (C) Western blot analysis of exosomal markers CD63, CD81, and TSG101 confirmed that the isolated EVs from murine serum samples include exosomes. Cytochrome C and nucleoporin were also analyzed as negative controls. Lysates from C2C12 cells served as controls. (D–I) Serum small EVs of DMSXL and WT mice ($n = 5$) were further analyzed for the presence of miR-223-3p (D), miR-24-3p (E), miR-1-3p (F), miR-133a-3p (G), miR-133b-3p (H), and miR-206-3p (I). All miRNA levels under investigation were found to be increased in circulating small EVs in DMSXL mice compared to WT. Graphs represent the relative expression of miRNA levels in DMSXL mice relative to controls. * $p < 0.05$; sEVs, small extracellular vesicles; Cl, cell lysates.




Figure 6. The endogenous levels of miR-223-3p are decreased in the heart of DMSXL mice

Heart tissues were harvested from 6-week-old DMSXL and control mice ($n = 5$), and the endogenous levels of miR-223-3p (A), miR-24-3p (B), miR-1-3p (C), miR-133a-3p (D), miR-133b-3p (E), and miR-206-3p (F) were measured. The expression levels of miR-223-3p were decreased in the cardiac tissue of DMSXL mice compared to WT mice. miR-24-3p and the four myomiR levels revealed no significant changes in DMSXL mice compared to controls. Graphs represent the relative expression of miRNA levels in DMSXL mice relative to WT mice. * $p < 0.05$.

and miR-206-3p, are elevated in the serum of DM1 patients compared to control subjects and, more importantly, their levels were determined to be associated with the disease progression.¹¹ Specifically, the myomiR levels were reported to be significantly elevated in DM1 patients with progressive muscle wasting compared to patients with non-progressive muscle wasting (stable patients), suggesting their potential use as monitoring biomarkers for the disease progression.¹¹ In a larger group of DM1 patients, eight miRNAs, miR-1, miR-27b, miR-133a, miR-133b, miR-140, miR-206, miR-454, and miR-574, were also validated as plasma-based biomarkers for DM1.¹⁴ Interestingly, we reported that the whole population of the four myomiRs is encapsulated within small EVs, which were also found to be enriched in exosomes, in the serum of DM1 patients. Their encapsulated levels were correlated to the progression of the disease.¹²


In this work we aimed to identify novel miRNA biomarkers for DM1 by analyzing, for the first time, the entire population of small RNA molecules in the serum samples from DM1 patients and healthy individuals. By performing high-throughput small RNA NGS analysis, we identified miRNAs that are altered in the serum of DM1 patients. Based on bioinformatics analysis and expression studies in literature, two novel miRNAs, miR-223-3p and miR-24-3p, were chosen for further investigation for their potential use as miRNA biomarkers. Notably, the four myomiRs, miR-1, miR-133a, miR-133b, and miR-206, that have been previously validated as blood biomarkers for DM1 were not listed as differentially expressed miRNAs with

high statistical significance.^{12,16,23,24} The low circulating myomiR levels in the blood of patients and the low sensitivity of the current NGS technology led to their detection with low statistical significance. miR-223-3p and miR-24-3p were further validated in a larger cohort of patients showing promising results. Specifically, both miRNAs were found to be significantly increased in the serum of DM1 patients compared to healthy individuals. ROC analysis showed that miR-223-3p is characterized by higher sensitivity and specificity than miR-24-3p. The sensitivity and specificity of

the miR-223-3p are almost the same as the four myomiRs previously reported as serum biomarkers of DM1, thus suggesting that these five miRNAs, miR-223-3p, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p, can discriminate DM1 patients from healthy individuals extremely well ($AUC = 0.96-0.98$).^{11,12} Conversely, miR-24-3p can discriminate DM1 patients from healthy individuals with slightly lower sensitivity and specificity ($AUC = 0.88$). Taking into consideration the interpatient variability observed in the DM1 patients of this study, which arises from the differences in the severity and progression of the symptoms of each patient, both miRNAs miR-223-3p and miR-24-3p can be suggested as reliable DM1 biomarkers.

We have previously reported that the four myomiRs, miR-1, miR-133a, miR-133b, and miR-206, circulating in the blood of DM1 patients are encapsulated within small EVs.¹² EVs are a heterogeneous group of membranous vesicles released from cells and tissues.^{52,53} They can be found in most of the biological fluids like serum, saliva, and urine, and their molecular cargo was suggested to be a promising source for the development of biomarkers.^{54,55} In order to further investigate the possible reasons underlying the existence of the six miRNAs in the blood of DM1 patients, the transgenic animal model for DM1, DMSXL, was used. DMSXL mice show molecular DM1 features such as muscle wasting, nuclear foci, and splicing defects as well as muscle dysfunction, reduced muscle strength, and low motor performance.³⁹ These mice also recapitulate some molecular features of DM1 leading to physiological abnormalities.³⁹ Although DMSXL mice share similar features with DM1 patients, there are no reports

Common and unique miRNA gene-targets



(legend on next page)

regarding the development of biomarkers in this animal model. Serum miRNA analysis showed that all six miRNAs, miR-24-3p, miR-223-3p, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p, are increased in the blood circulation of the diseased DMSXL mice relative to the healthy littermate controls. More importantly, we demonstrated that small EVs circulating in the serum of the DMSXL mice encapsulate elevated levels of these miRNAs compared to WT mice. This implies that all six miRNAs are abnormally packaged and released in the blood circulation in the DMSXL mouse model. A limitation of the present study is that the method employed for the isolation of the small EVs results in the co-isolation of non-vesicular impurities together with the membranous vesicles. However, small EVs, such as exosomes, were also isolated, as demonstrated by the analysis of the vesicles' properties. It is noteworthy that the encapsulation of the four myomiRs within small EVs in the blood of DMSXL mice is consistent with the reported results in DM1 patients, implying that DM1 patients and DMSXL mice share similar abnormal pathways for the miRNA-sorting mechanisms within the secreted small EVs.¹² These results provide novel evidence for the potential use of these miRNAs as biomarkers in the DMSXL animal model, facilitating their use not only for the study of DM1 pathogenesis but also for the development of efficient DM1 therapies. Whether the two new biomarkers reported in this study, miR-223-3p and miR-24-3p, are specific to the DM1 pathology remains to be elucidated in future studies.

An in-depth investigation of the levels of the six miRNAs in skeletal muscle and cardiac tissues in DMSXL mice revealed notable differences in the endogenous expression levels of these miRNAs. In particular, the endogenous levels of miR-24-3p as well as the four myomiRs showed no significant changes in the five skeletal muscle tissues of the hindlimbs of DMSXL mice compared to controls. Similarly, none of the four myomiRs or miR-24-3p showed any difference in their endogenous expression levels in heart tissues of DMSXL mice relative to unaffected mice. These results show that the endogenous expression of the five miRNAs, miR-24-3p, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p, is not affected by the disease, either in skeletal muscle or in the cardiac tissues in DMSXL mice. Thus, it is suggested that DM1-associated pathways possibly underlying the abnormal release of the five miRNAs in the blood of the affected DMSXL mice are yet to be discovered. Further investigation of the involvement of these miRNAs in the pathogenesis of secondary symptoms will shed light on the multisystemic character of DM1 in human patients.

Interestingly, the endogenous expression levels of miR-223-3p were found to be significantly decreased in five skeletal muscles and the heart of DMSXL mice compared to asymptomatic WT mice. miR-

223-3p is an inflammatory miRNA and has been reported to be involved in the promotion of skeletal muscle regeneration after injury in mice, by regulating pro- and anti-inflammatory signals.⁷⁶ Furthermore, miR-223-3p has been associated with dysregulated glucose uptake in murine cardiomyocytes and with heart failure in diabetic patients.⁷⁷ Taking into consideration our findings and published reports, it is suggested that miR-223-3p is involved in pathways underlying the pathogenesis of DM1-related symptoms in the DMSXL muscles and, therefore, probably associated with similar phenotypes in DM1 patients. For instance, the decreased miR-223-3p levels in skeletal muscles of DMSXL mice may be related to dysregulated muscle regeneration activity, leading to the observed muscle wasting and atrophy. Moreover, the low endogenous levels of miR-223-3p and its elevated circulating levels in blood may be ascribed to the inability of tissues to compensate the loss of this specific miRNA following its secretion into the extracellular environment. Furthermore, the lower levels of miR-223-3p in skeletal muscle tissues and heart possibly affect the expression of its targets, thus causing downstream pathogenic DM1 events in these tissues, such as insulin resistance.⁷⁷

Bioinformatics analysis of the human miR-24-3p and miR-223-3p showed that both miRNAs are implicated in the regulation of the nervous system development and mediate CNS homeostasis. It has been previously reported that miR-24-3p is implicated in pathways regulating neuronal differentiation, and, more importantly it was proposed as a plasma-based biomarker for CNS diseases such as Parkinson disease.^{56,57} In addition, miR-223-3p has been described to protect neural cells from degeneration by regulating the expression of neuroprotective genes.^{58,59} The CNS is affected in DM1 patients, who show patterns of psychological dysfunction, intellectual disability, excessive daytime sleepiness, and neuropathological abnormalities. Taking into consideration the reported brain-specific functions of the two miRNAs, the CNS-related symptoms in DM1 may be associated with the observed upregulated detection of these miRNAs in the blood of DM1 patients.⁶⁰

In-depth bioinformatics analysis of mouse miR-24-3p, miR-223-3p, and the four myomiRs showed that only miR-24-3p shares a common biological process with the four myomiRs, neurofilament cytoskeleton organization, whereas miR-223-3p was found to be involved in independent biological processes with the other investigated miRNAs, such as CNS development and cardiac muscle function. These results provide evidence that the two novel miRNAs reported in this study are involved in different pathways in comparison with the four myomiRs. Overall, the decreased miR-223-3p endogenous levels and the different biological processes compared to the other

Figure 7. Target prediction and pathways analysis of miR-223-3p, miR-24-3p, and the four myomiRs

(A) Gene target prediction analysis of the investigated human miR-223-3p and miR-24-3p. Human miR-223-3p and miR-24-3p were predicted to share five common gene targets. (B) Gene target prediction analysis of the mouse miRNAs showed that miR-223-3p and miR-24-3p have not any common predicted targets; myomiRs share five common gene targets with miR-223-3p and only one with miR-24-3p. (C–F) Pathway analysis of the predicted target genes of the miRNAs showed different biological processes that are predicted to be involved: pathway analysis of human miR-223-3p and miR-24-3p (C), mouse miR-24-3p (D), mouse miR-223-3p (E), and mouse myomiRs (F). hsa, *Homo sapiens*; mmu, *Mus musculus*.

miRNAs that involve miR-223-3p provide information for possibly novel pathways that may be altered in DM1.

In conclusion, we investigated for the first time the entire small RNA population in the serum of DM1 patients, and we suggested two novel miRNAs, miR-24-3p and miR-223-3p, that can be used as potential biomarkers for the disease. We further examined the levels of miR-223-3p, miR-24-3p, and the four myomiRs, miR-1-3p, miR-133a-3p, miR-133b-3p, and miR-206-3p, which were previously suggested as monitoring biomarkers for the disease progression, in the DMSXL mouse model. Both miRNAs as well as the four myomiRs were found to be increased circulating in the serum of DMSXL mice compared to controls and were proposed for the first time as potential biomarkers for this DM1 animal model. Importantly, we showed that the endogenous levels of miR-223-3p are reduced in skeletal muscles and heart tissues of DMSXL mice, providing significant evidence for its role in the manifestation of the disease.

MATERIALS AND METHODS

Participant inclusion, blood collection, and isolation of serum

The study was permitted by the National Bioethics Committee of Cyprus, and experiments were carried out according to the Declaration of Helsinki principles. All human individuals provided a written informed consent to participate and deliver blood specimens for the project. All DM1 patients were formerly diagnosed by (1) the Diagnostic Department, Cyprus Institute of Neurology and Genetics using Southern blot technique, (2) the Diagnostic Department, Eginitio Hospital in Greece, and (3) the Medical University of Warsaw in Poland. For the purposes of the project, all patients were physically examined prior to study enrollment. Healthy participants did not have a family history of muscle disease. Information regarding the gender, age, progression, age of onset, MIRS scale, and severity of the DM1 patients is included in Table S1. The age and gender of the healthy participants are also summarized in Table S1. After clinical examination, a total of 4 mL of whole blood was drawn from all participants and placed in serum collection tubes (BD Vacutainer, Franklin Lakes, NJ, USA). For DM1 patients, blood collection for miRNA analysis was performed after their last clinical examination. Blood samples were allowed to form a clot for an hour at room temperature before being centrifuged at 3,000 rpm for 5 min at room temperature. Serum was subsequently isolated from the samples and stored at -80°C in DNase- and RNase-free tubes.

Small RNA-next-generation sequencing

After serum collection, total RNA, including miRNAs, was extracted from serum samples with the miRNeasy Mini Kit (QIAGEN, Hilden, Germany), according to the manufacturer's instructions. Small RNA-NGS libraries were constructed from 5 μL of RNA with the QIAseq miRNA Library Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Library concentrations were measured with Qubit dsDNA HS Assay Kit (Thermo Fisher, Waltham, MA, USA). Quality and concentration of libraries were determined by real-time PCR. Libraries were sequenced on a NextSeq 500 System (Il-

lumina, San Diego, CA, USA) in 1×75 bp single-end sequencing mode.

Raw RNA-NGS data analysis

The raw data were processed for QIAseq adaptor filtering and unique molecular identifier (UMI)-demultiplexing with Trimmomatic and UMI-tool software.⁶¹ The UMI sequences were initially extracted, the raw reads were then mapped to Genome Reference Consortium GRCh37 with Bowtie1 version 1.2.2, and then deduplication was performed with UMI-tools in order to collapse the duplicated reads (i.e., the reads with the same UMI).⁶² Quantification of mapped reads was performed with the HTSEQ-count tool.⁶³ All mature miRNAs were quantified according to the General Feature Format (GFF) file that was retrieved from the miRBase database in July 2019.⁶⁴ Differential expression analysis was performed using the EdgeR package version 3.8 of R Bioconductor for the identification of differentially expressed miRNAs (DEMs) between patient and control samples.⁶⁵ The miRNA count matrices were normalized for RNA composition between libraries with a trimmed mean of M-values (TMM) normalization.⁶⁶ We kept the miRNAs with a minimum requirement of 1 count per million (CPM) across two or more libraries. The Quasi-Likelihood F-test (QLF) was used as a statistical method to calculate the DEMs provided by the EdgeR package.⁶⁷ The EdgeR analysis returned the following: log2FC, logCPM, p value, false discovery rate (FDR) and F-value for each miRNA. Sequencing data are available through the European Nucleotide Archive (ENA) (<https://www.ebi.ac.uk/ena/browser/home>) supported by the European Bioinformatics Institute (EBI) under the following accession ENA: PRJEB46413.

Animal experiments

Housing and handling of all mice were performed according to European Directive 2010/63/EE and Cyprus Legislation for the protection and welfare of animals, Laws 1994–2013. Heterozygous transgenic DMSXL breeders were provided by G. Gourdon (Institute of Myology, Paris, France). The transgenic mouse model DMSXL (>90% C57BL/6 background) carries 45 kb genomic DNA cloned from a patient with DM1.⁴⁰ Mice carrying two copies of the transgene (homozygous; DMSXL) are distinguishable from the 2nd to 3rd week of their life, as they show very slow growth. Moreover, DMSXL mice are characterized by high mortality rate, muscle weakness, and mental abnormalities compared to healthy mice of the same litter.³⁹ Six-week-old gender-matched DMSXL mice and control mice carrying no copy of the transgene (WT) of both sexes were used for this study. Five skeletal muscle tissues located on the hindlimbs of mice (EDL, soleus, TA, gastrocnemius, quadriceps) and hearts were harvested from the mice and homogenized with Precellys 24 (Bertin Technologies, Montbonnot-Saint-Martin, France). Total endogenous RNA, enriched in miRNAs, was extracted from tissue lysates with the mirVana miRNA Isolation Kit (Invitrogen, Carlsbad, CA, USA) based on the manufacturer's instructions. Blood samples were also collected by orbital blood sampling technique in EDTA-free tubes and left to clot for 20 min at room temperature before centrifugation at 2,000 rcf at room temperature. Serum was subsequently isolated from the samples and stored at -80°C until further use. Total RNA, enriched in

Table 1. Source edge list databases for miRNA–gene target predictions

Source DB	Database file	Edge list	Kappa score threshold
Human miRNA edge lists			
CluePedia	CluePedia_microRNA.org-human_predictions_S_C_aug2010.txt.gz	mirsvr_score*(−1) human_predictions_S_C_aug2010	0.6
miRDB ⁷²	miRDB_v6.0_prediction_hsa_based_on_miRBase_22_17.04.2019.txt.gz	miRanda-hsa-Score_miRDB_v6.0_prediction_based_on_miRBase_22	0.8
mirTarBase ⁷³	mirTarBase.validated.miRNAs_15.06.2016.txt	validated miRTarBase	0.6
miRecords ⁷⁴	miRecords.umn.edu.validated.miRNAs.2010-11-25.txt.gz	validated miRNA	0.6
Mouse miRNA edge lists			
CluePedia	CluePedia_microRNA.org-mouse_predictions_S_C_aug2010.txt.gz	mirsvr_score*(−1) mouse_predictions_S_C_aug2010	0.6
miRDB ⁷²	miRDB_v6.0_prediction_mmu_based_on_miRBase_22_17.04.2019.txt.gz	miRanda-hsa-Score_miRDB_v6.0_prediction_based_on_miRBase_22	0.8
mirTarBase ⁷³	mirTarBase.validated.miRNAs_17.06.2016.txt	validated miRTarBase	0.6
miRecords ⁷⁴	miRecords.umn.edu.validated.miRNAs.2010-11-25.txt.gz	validated miRNA	0.6

miRNAs, was extracted from 100 μ L serum samples with the mir-Vana PARIS Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.

Isolation of small EVs and encapsulated miRNAs

Small EVs were isolated from 100 μ L serum samples of mice with ExoQuick Exosome Precipitation Solution (System Biosciences, Palo Alto, CA, USA) according to the manufacturer's instructions. Small EVs were allowed to precipitate at 4°C overnight, followed by centrifugation at 1,500 rcf for 30 min. Total RNA, enriched in miRNAs, was extracted from the small EV pellets with the Total Exosome RNA and Protein Isolation Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.

Scanning electron microscopy

Small EVs isolated from serum of mice were subjected to fixation with 4% paraformaldehyde (PFA) for 10 min followed by phosphate-buffered saline (PBS) washes. Samples were mounted on aluminum specimen stubs and sputtered with gold/palladium (Au/Pd) for 15 s. High-resolution scanning electron microscopic analysis was performed at 20.00 kV (magnification of 60,000) in a FEI Quanta 200 microscope, and images were processed with the MountainsMap SEM Topo version 7.3 software.

Tunable resistive pulse sensing analysis

Quantification and size analysis of small EVs was performed with the qNano Gold platform (Izon Science, Oxford, UK) combining tunable nanopores with proprietary data capture. Small EVs were diluted in filtered electrolyte and compared to calibration particles CPC200, all provided by Izon Science. Samples were measured with the nanopore NP200 (A44687, Izon Science, Oxford, UK) at 45-mm stretch (voltage: 0.78 V and pressure: 10 mbar). Particles were detected as short pulses of the current, and data analysis was

carried out with Izon Control Suite software v3.3 (Izon Science, Oxford, UK).

Western blot analysis of small EVs

Protein samples were prepared by lysing the serum small EVs in buffer containing 150 mM NaCl, 10 mM Tris-HCl (pH = 7.6), 10% glycerol, 0.5% Tween, and 10 mM mercaptoethanol, supplemented with 2 $\times$ EDTA-free Protease Inhibitor Cocktail. The lysate was sonicated and then centrifuged at 4°C. Protein extracts of 40–60 μ g were separated on a 12% SDS-PAGE, transferred on a membrane, and then incubated overnight at 4°C with primary antibodies specific for anti-CD63 (Abcam, Cambridge, UK), anti-CD81 (Abcam, Cambridge, UK), anti-TSG101 (Santa Cruz Biotechnology, Dallas, TX, USA), anti-Nucleoporin p62 (BD Biosciences, Franklin Lakes, NJ, USA), and anti-Cytochrome C (BD Biosciences, Franklin Lakes, NJ, USA). Subsequently, the membranes were incubated for 2 h at room temperature with anti-mouse immunoglobulin G (IgG) or anti-rabbit IgG horseradish peroxidase (HRP)-conjugated secondary antibodies (Santa Cruz Biotechnology, Dallas, TX, USA). Proteins were visualized with the UVP BioSpectrum 810 Imaging System.

Quantitative real-time PCR of miRNAs

A total of 10 ng of the extracted RNA was subjected to reverse transcriptase PCR using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions. Real-time PCR amplification was performed with TaqMan MicroRNA Assays specific for miR-223-3p (Assay ID: 002295; Cat. Num.: 4427975), miR-24-3p (Assay ID: 000402; Cat. Num.: 4427975), miR-1-3p (Assay ID: 002222; Cat. Num.: 4427975), miR-133a-3p (Assay ID: 002246; Cat. Num.: 4427975), miR-133b-3p (Assay ID: 002247; Cat. Num.: 4427975), and miR-206-3p (Assay ID: 000510; Cat. Num.: 4427975) (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. miRNA levels

were normalized to miR-16-5p (Assay ID: 000391; Cat. Num.: 4427975) for patients' serum samples, to snoR-135 (Assay ID: 001230; Cat. Num.: 4427975) for mouse tissues, and to the spike-in control cel-miR-39 (Assay ID: 000200; Cat. Num.: 4427975) for the encapsulated miRNA levels in the small EVs (Applied Biosystems, Foster City, CA, USA). Data analysis was performed with SDS 2.4 Real-Time PCR data analysis software (Applied Biosystems, Foster City, CA, USA).

Statistical analysis

Statistical analysis was performed as described previously.⁶⁸ Δ Threshold cycle (Ct) values were calculated as Ct (miR-16-5p for human serum, snoRNA-135 for mouse tissue, and cel-miR-39 for mice serum small EVs) minus Ct (miRNA). Normality of the distribution of each of the miRNA variables was assessed with the Shapiro-Wilk test; non-parametric methods (exact Wilcoxon and Kruskal-Wallis tests) were used in the analyses. A two-tailed p value of 0.05 was used to determine statistical significance. A Bonferroni adjustment was made to the alpha level (from 0.05 to 0.00069) to account for multiple comparisons (number of comparisons = 72). Spearman's correlation analyses were carried out to assess correlations between miRNA levels and study participant demographic, clinical, and molecular characteristics. Differences between DM1 patients and healthy participants were assessed with chi-square (categorical variables) and Wilcoxon (continuous variables) tests. In addition, ROC curves were used to determine the sensitivity and specificity of the assays in discriminating between DM1 patients and healthy participants. The AUC for the ROC curves was calculated. All analyses were performed with SAS v.9.4 (SAS Institute) software. Data illustrated in figures are mean values $\pm$ SE after normalization. Data in illustrations are relative expressions of DMSXL mice compared to controls. Regarding the statistical analysis of the serum small EVs in DMSXL mice, p values were calculated assuming a one-sided test based on the hypothesis that the miRNA values would be elevated in diseased mice compared to WT, following the patients' results.

Bioinformatics analysis

The human and mouse miRNAs of interest were imported in Cytoscape v3.7.2. using the ClueGO v2.5.5⁶⁹ and CluePedia v1.5.5.^{70,71} plugins and analyzed based on the following grouping:

- (a) Human: hsa-miR-24-3p and hsa-miR-223-3p
- (b) Mouse: mmu-miR-24-3p
- (c) Mouse: mmu-miR-223-3p
- (d) Mouse: mmu-miR-1-3p, mmu-miR-206-3p, mmu-miR-133a-3p, and mmu-miR-133b-3p

The first group was created to identify any common prediction target genes in human between miR-223-3p and miR-24-3p. The other three groups were formed for the identification of the predicted targets in mouse of miR-223-3p and miR-24-3p as well as the four myomiRs. Each set was screened against a number of reference miRNA target edge lists that are available through CluePedia sourced from the databases shown in Table 1. Using CluePedia's enrichment function, we constructed bipartite networks connecting the miRNAs in each group with their respective predicted gene targets with the default

kappa score for each edge list in Table 1 and an arbitrary limit of 50 genes per miRNA. The predicted gene targets for each disease were used as an input in the GO enrichment analysis tool run by the PANTHER Classification System server.⁷²⁻⁷⁴ Functional analysis was performed against the *Homo sapiens* and *Mus musculus* GO Biological Process database, returning the most significantly enriched GO terms. The GO term set was further processed in R in order to isolate the terms that are related to neuronal and muscle-related processes. GO term level mapping was performed through ClueGO's *pre-selected functions* mode and plotted with R's ggplot2 package.⁷⁵

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.omtm.2021.09.007>.

ACKNOWLEDGMENTS

This Project (POST-DOC/0916/0235) was co-financed by the European Regional Development Fund and the Republic of Cyprus through the Research and Innovation Foundation. This work was also supported by A. G. Leventis Foundation. The authors would like to thank Anna Katsioloudi for her support on TRPS analysis. H.L. receives support from the Canadian Institutes of Health Research (Foundation Grant FDN-167281), the Canadian Institutes of Health Research and Muscular Dystrophy Canada (Network Catalyst Grant for NMD4C), the Canada Foundation for Innovation (CFI-JELF 38412), and the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950-232279). M.T., A.O., A.C.K., and G.M.S. were funded by European Commission Research Executive Agency Grant BIORISE [number 669026], under the Spreading Excellence, Widening Participation, Science with and for Society Framework.

AUTHOR CONTRIBUTIONS

L.A.P. conceived the study. L.A.P., A.K., and D.K. designed the study. D.K. conducted most of the experiments and developed the data. A.K. and C.M. performed the mouse handling and the tissue isolation. C.M. performed the WB analysis. D.K. and C.M. performed real-time PCR analysis. A.C.K., A.O., M.T., and G.M.S. performed the bioinformatics analysis. A.A., M.P., and K.K. performed SEM and TRPS experiments. A.L., K.J., N.N., G. Gorman, C.T., H.L., G.K.P., C.P., E.K., and E.Z.P. provided the serum samples, clinical data, and clinical expertise. G. Gourdon provided the mouse animal model. T.C.K. carried out statistical analysis. L.A.P., D.K., and A.K. analyzed and interpreted the data. D.K. and A.K. wrote the manuscript. L.A.P. coordinated the study. All authors read and approved the final manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

- Harper, P.S. (1989). Postoperative complications in myotonic dystrophy. *Lancet* 2, 1269.
- Larkin, K., and Fardaei, M. (2001). Myotonic dystrophy—a multigene disorder. *Brain Res. Bull.* 56, 389–395.

3. Aslanidis, C., Jansen, G., Amemiya, C., Shutler, G., Mahadevan, M., Tsilfidis, C., Chen, C., Alleman, J., Wormskamp, N.G., Vooijs, M., et al. (1992). Cloning of the essential myotonic dystrophy region and mapping of the putative defect. *Nature* 355, 548–551.
4. Machuca-Tzili, L., Brook, D., and Hilton-Jones, D. (2005). Clinical and molecular aspects of the myotonic dystrophies: a review. *Muscle Nerve* 32, 1–18.
5. Foff, E.P., and Mahadevan, M.S. (2011). Therapeutics development in myotonic dystrophy type 1. *Muscle Nerve* 44, 160–169.
6. Turner, C., and Hilton-Jones, D. (2014). Myotonic dystrophy: diagnosis, management and new therapies. *Curr. Opin. Neurol.* 27, 599–606.
7. Udd, B., and Krahe, R. (2012). The myotonic dystrophies: molecular, clinical, and therapeutic challenges. *Lancet Neurol.* 11, 891–905.
8. Koch, A.J., Pereira, R., and Machado, M. (2014). The creatine kinase response to resistance exercise. *J. Musculoskelet. Neuronal Interact.* 14, 68–77.
9. Heatwole, C.R., Miller, J., Martens, B., and Moxley, R.T., 3rd (2006). Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1. *Arch. Neurol.* 63, 1149–1153.
10. Nakamori, M., Sobczak, K., Puwanant, A., Welle, S., Eichinger, K., Pandya, S., Dekdebrun, J., Heatwole, C.R., McDermott, M.P., Chen, T., et al. (2013). Splicing biomarkers of disease severity in myotonic dystrophy. *Ann. Neurol.* 74, 862–872.
11. Koutsoulidou, A., Kyriakides, T.C., Papadimas, G.K., Christou, Y., Kararizou, E., Papanicolaou, E.Z., and Phylactou, L.A. (2015). Elevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress. *PLoS ONE* 10, e0125341.
12. Koutsoulidou, A., Photiades, M., Kyriakides, T.C., Georgiou, K., Prokopi, M., Kapnisi, K., Lusakowska, A., Nearchou, M., Christou, Y., Papadimas, G.K., et al. (2017). Identification of exosomal muscle-specific miRNAs in serum of myotonic dystrophy patients relating to muscle disease progress. *Hum. Mol. Genet.* 26, 3285–3302.
13. Perfetti, A., Greco, S., Bugiardi, N., Cardani, R., Gaia, P., Gaetano, C., Meola, G., and Martelli, F. (2014). Plasma microRNAs as biomarkers for myotonic dystrophy type 1. *Neuromuscul. Disord.* 24, 509–515.
14. Perfetti, A., Greco, S., Cardani, R., Fossati, B., Cuomo, G., Valaperta, R., Ambrogio, F., Cortese, A., Botta, A., Mignarri, A., et al. (2016). Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1. *Sci. Rep.* 6, 38174.
15. Koehorst, E., Ballester-Lopez, A., Archavala-Gomez, V., Martínez-Piñeiro, A., and Nogales-Gadea, G. (2020). The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I. *J. Clin. Med.* 9, 3939.
16. Hanke, M., Hoefig, K., Merz, H., Feller, A.C., Kausch, I., Jocham, D., Warnecke, J.M., and Szczakiel, G. (2010). A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. *Urol. Oncol.* 28, 655–661.
17. Gilad, S., Meiri, E., Yogeve, Y., Benjamin, S., Lebanony, D., Yerushalmi, N., Benjamin, H., Kushnir, M., Cholkh, H., Melamed, N., et al. (2008). Serum microRNAs are promising novel biomarkers. *PLoS ONE* 3, e3148.
18. Li, L.M., Hu, Z.B., Zhou, Z.X., Chen, X., Liu, F.Y., Zhang, J.F., Shen, H.B., Zhang, C.Y., and Zen, K. (2010). Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. *Cancer Res.* 70, 9798–9807.
19. Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L.E., and Galas, D.J. (2009). Circulating microRNAs, potential biomarkers for drug-induced liver injury. *Proc. Natl. Acad. Sci. USA* 106, 4402–4407.
20. Wagner, J., Riawanto, M., Besler, C., Knaus, A., Fichtlscherer, S., Röxe, T., Zeiher, A.M., Landmesser, U., and Dimmeler, S. (2013). Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. *Arterioscler. Thromb. Vasc. Biol.* 33, 1392–1400.
21. Vickers, K.C., Palmisano, B.T., Shoucri, B.M., Shamburek, R.D., and Remaley, A.T. (2011). MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat. Cell Biol.* 13, 423–433.
22. Hunter, M.P., Ismail, N., Zhang, X., Aguda, B.D., Lee, E.J., Yu, L., Xiao, T., Schafer, J., Lee, M.L., Schmittgen, T.D., et al. (2008). Detection of microRNA expression in human peripheral blood microvesicles. *PLoS ONE* 3, e3694.
23. Pegoraro, V., Cudia, P., Baba, A., and Angelini, C. (2020). MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy. *Neurol. Sci.* 41, 2953–2960.
24. Ambrose, K.K., Ishak, T., Lian, L.H., Goh, K.J., Wong, K.T., Ahmad-Annuar, A., and Thong, M.K. (2017). Deregulation of microRNAs in blood and skeletal muscles of myotonic dystrophy type 1 patients. *Neurol. India* 65, 512–517.
25. Ludwig, N., Leidinger, P., Becker, K., Backes, C., Fehlmann, T., Pallasch, C., Rheinheimer, S., Meder, B., Stähler, C., Meese, E., and Keller, A. (2016). Distribution of miRNA expression across human tissues. *Nucleic Acids Res.* 44, 3865–3877.
26. Lim, K.R., Maruyama, R., and Yokota, T. (2017). Eteplirsin in the treatment of Duchenne muscular dystrophy. *Drug Des. Devel. Ther.* 11, 533–545.
27. Sun, Q., Zhang, Y., Yang, G., Chen, X., Zhang, Y., Cao, G., Wang, J., Sun, Y., Zhang, P., Fan, M., et al. (2008). Transforming growth factor-beta-regulated miR-24 promotes skeletal muscle differentiation. *Nucleic Acids Res.* 36, 2690–2699.
28. Sun, Y., Wang, H., Li, Y., Liu, S., Chen, J., and Ying, H. (2018). miR-24 and miR-122 Negatively Regulate the Transforming Growth Factor- β /Smad Signaling Pathway in Skeletal Muscle Fibrosis. *Mol. Ther. Nucleic Acids* 11, 528–537.
29. Ismael, A., Kim, J.S., Kirk, J.S., Smith, R.S., Bohannon, W.T., and Koutakis, P. (2019). Role of Transforming Growth Factor- β in Skeletal Muscle Fibrosis: A Review. *Int. J. Mol. Sci.* 20, 2446.
30. Greco, S., De Simone, M., Colussi, C., Zaccagnini, G., Fasanaro, P., Pescatori, M., Cardani, R., Perbellini, R., Isaia, E., Sale, P., et al. (2009). Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. *FASEB J.* 23, 3335–3346.
31. Poel, D., Buffart, T.E., Oosterling-Jansen, J., Verheul, H.M., and Voortman, J. (2018). Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. *Exp. Mol. Med.* 50, e454.
32. Roth, C., Rack, B., Müller, V., Janni, W., Pantel, K., and Schwarzenbach, H. (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. *Breast Cancer Res.* 12, R90.
33. Wang, X., Zhang, X., Yuan, J., Wu, J., Deng, X., Peng, J., Wang, S., Yang, C., Ge, J., and Zou, Y. (2018). Evaluation of the performance of serum miRNAs as normalizers in microRNA studies focused on cardiovascular disease. *J. Thorac. Dis.* 10, 2599–2607.
34. Turchinovich, A., Weiz, L., Langhein, A., and Burwinkel, B. (2011). Characterization of extracellular circulating microRNA. *Nucleic Acids Res.* 39, 7223–7233.
35. Arroyo, J.D., Chevillet, J.R., Kroh, E.M., Ruf, I.K., Pritchard, C.C., Gibson, D.F., Mitchell, P.S., Bennett, C.F., Pogosova-Agadjanyan, E.L., Stirewalt, D.L., et al. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc. Natl. Acad. Sci. USA* 108, 5003–5008.
36. Turchinovich, A., and Burwinkel, B. (2012). Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. *RNA Biol.* 9, 1066–1075.
37. Sztrybel, M., Szabó, L., Dobrosi, N., Fodor, J., Szentesi, P., Almásy, J., Magyar, Z.E., Dienes, B., and Csernoch, L. (2020). From Mice to Humans: An Overview of the Potentials and Limitations of Current Transgenic Mouse Models of Major Muscular Dystrophies and Congenital Myopathies. *Int. J. Mol. Sci.* 21, 8935.
38. Braz, S.O., Acquire, J., Gourdon, G., and Gomes-Pereira, M. (2018). *Of Mice and Men: Advances in the Understanding of Neuromuscular Aspects of Myotonic Dystrophy*. *Front. Neurol.* 9, 519.
39. Huguet, A., Medja, F., Nicole, A., Vignaud, A., Guiraud-Dogan, C., Ferry, A., Decostre, V., Hogrel, J.Y., Metzger, F., Hoeflich, A., et al. (2012). Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus. *PLoS Genet.* 8, e1003043.
40. Gomes-Pereira, M., Foirey, L., Nicole, A., Huguet, A., Junien, C., Munnich, A., and Gourdon, G. (2007). CTG trinucleotide repeat “big jumps”: large expansions, small mice. *PLoS Genet.* 3, e52.
41. Kalluri, R., and LeBleu, V.S. (2020). The biology, function, and biomedical applications of exosomes. *Science* 367, eaau6977.
42. Uemura, N., Tanaka, H., Niimura, T., Hashiguchi, N., Yoshimura, M., Terashi, S., and Kanehisa, T. (1973). Electrophysiological and histological abnormalities of the heart in myotonic dystrophy. *Am. Heart J.* 86, 616–624.

43. Pelargonio, G., Dello Russo, A., Sanna, T., De Martino, G., and Bellocchi, F. (2002). Myotonic dystrophy and the heart. *Heart* 88, 665–670.
44. Wang, J., Huang, W., Xu, R., Nie, Y., Cao, X., Meng, J., Xu, X., Hu, S., and Zheng, Z. (2012). MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. *J. Cell. Mol. Med.* 16, 2150–2160.
45. Liu, X., Xu, Y., Deng, Y., and Li, H. (2018). MicroRNA-223 Regulates Cardiac Fibrosis After Myocardial Infarction by Targeting RASA1. *Cell. Physiol. Biochem.* 46, 1439–1454.
46. Guo, C., Deng, Y., Liu, J., and Qian, L. (2015). Cardiomyocyte-specific role of miR-24 in promoting cell survival. *J. Cell. Mol. Med.* 19, 103–112.
47. Kang, B., Li, W., Xi, W., Yi, Y., Ciren, Y., Shen, H., Zhang, Y., Jiang, H., Xiao, J., and Wang, Z. (2017). Hydrogen Sulfide Protects Cardiomyocytes against Apoptosis in Ischemia/Reperfusion through MiR-1-Regulated Histone Deacetylase 4 Pathway. *Cell. Physiol. Biochem.* 41, 10–21.
48. Zhai, C., Qian, Q., Tang, G., Han, B., Hu, H., Yin, D., Pan, H., and Zhang, S. (2017). MicroRNA-206 Protects against Myocardial Ischaemia-Reperfusion Injury in Rats by Targeting Gadd45 β . *Mol. Cells* 40, 916–924.
49. Mi, H., Muruganujan, A., Ebert, D., Huang, X., and Thomas, P.D. (2019). PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. *Nucleic Acids Res.* 47 (D1), D419–D426.
50. Mi, H., Muruganujan, A., Huang, X., Ebert, D., Mills, C., Guo, X., and Thomas, P.D. (2019). Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). *Nat. Protoc.* 14, 703–721.
51. Koutsoulidou, A., and Phylactou, L.A. (2020). Circulating Biomarkers in Muscular Dystrophies: Disease and Therapy Monitoring. *Mol. Ther. Methods Clin. Dev.* 18, 230–239.
52. Raposo, G., and Stoorvogel, W. (2013). Extracellular vesicles: exosomes, microvesicles, and friends. *J. Cell Biol.* 200, 373–383.
53. Yáñez-Mó, M., Siljander, P.R., Andreu, Z., Zavec, A.B., Borràs, F.E., Buzas, E.I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015). Biological properties of extracellular vesicles and their physiological functions. *J. Extracell. Vesicles* 4, 27066.
54. Park, N.J., Zhou, H., Elashoff, D., Henson, B.S., Kastratovic, D.A., Abemayor, E., and Wong, D.T. (2009). Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. *Clin. Cancer Res.* 15, 5473–5477.
55. Zubakov, D., Boersma, A.W., Choi, Y., van Kuijk, P.F., Wiemer, E.A., and Kayser, M. (2010). MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation. *Int. J. Legal Med.* 124, 217–226.
56. Kang, M.J., Park, S.Y., and Han, J.S. (2019). MicroRNA-24-3p regulates neuronal differentiation by controlling hippocampal expression. *Cell. Mol. Life Sci.* 76, 4569–4580.
57. Uwatoko, H., Hama, Y., Iwata, I.T., Shirai, S., Matsushima, M., Yabe, I., Utsumi, J., and Sasaki, H. (2019). Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson's disease. *Mol. Brain* 12, 49.
58. Harraz, M.M., Eacker, S.M., Wang, X., Dawson, T.M., and Dawson, V.L. (2012). MicroRNA-223 is neuroprotective by targeting glutamate receptors. *Proc. Natl. Acad. Sci. USA* 109, 18962–18967.
59. Morquette, B., Jużwik, C.A., Drake, S.S., Charabati, M., Zhang, Y., Lécuyer, M.A., Galloway, D.A., Dumas, A., de Faria Junior, O., Paradis-Isler, N., et al. (2019). MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis. *Brain* 142, 2979–2995.
60. de León, M.B., and Cisneros, B. (2008). Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms. *J. Neurosci. Res.* 86, 18–26.
61. Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30, 2114–2120.
62. Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* 10, R25.
63. Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31, 166–169.
64. Griffiths-Jones, S. (2010). miRBase: microRNA sequences and annotation. *Curr. Protoc. Bioinformatics Chapter 12*. Unit 12 19 11–10. 20205188.
65. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 26, 139–140.
66. Robinson, M.D., and Oshlack, A. (2010). A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol.* 11, R25.
67. Lund, S.P., Nettleton, D., McCarthy, D.J., and Smyth, G.K. (2012). Detecting differential expression in RNA-sequence data using quasi-likelihood with shrunken dispersion estimates. *Stat. Appl. Genet. Mol. Biol.* 11, /j/sagmb.2012.11.issue-5/1544-6115.1826/1544-6115.1826.xml.
68. Yuan, J.S., Reed, A., Chen, F., and Stewart, C.N., Jr. (2006). Statistical analysis of real-time PCR data. *BMC Bioinformatics* 7, 85.
69. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* 13, 2498–2504.
70. Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.H., Pagès, F., Trajanoski, Z., and Galon, J. (2009). ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* 25, 1091–1093.
71. Bindea, G., Galon, J., and Mlecnik, B. (2013). CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. *Bioinformatics* 29, 661–663.
72. Wong, N., and Wang, X. (2015). miRDB: an online resource for microRNA target prediction and functional annotations. *Nucleic Acids Res.* 43, D146–D152.
73. Chou, C.H., Shrestha, S., Yang, C.D., Chang, N.W., Lin, Y.L., Liao, K.W., Huang, W.C., Sun, T.H., Tu, S.J., Lee, W.H., et al. (2018). miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. *Nucleic Acids Res.* 46 (D1), D296–D302.
74. Xiao, F., Zuo, Z., Cai, G., Kang, S., Gao, X., and Li, T. (2009). miRecords: an integrated resource for microRNA-target interactions. *Nucleic Acids Res.* 37, D105–D110.
75. Wickham, H. (2011). ggplot2. *Wiley Interdiscip. Rev. Comput. Stat.* 3, 180–185.
76. Cheng, N., Liu, C., Li, Y., Gao, S., Han, Y.-C., Wang, X., et al. (2020). MicroRNA-223-3p promotes skeletal muscle regeneration by regulating inflammation in mice. *J Biol Chem* 295, 10212–10223. <https://doi.org/10.1074/jbc.RA119.012263>.
77. Taibi, F., Metzinger-Le Meuth, V., Massy, Z.A., and Metzinger, L. (2014). miR-223: An inflammatory oncomiR enters the cardiovascular field. *Biochim Biophys Acta* 1842, 1001–1009. <https://doi.org/10.1016/j.bbdis.2014.03.005>.